23:08 , Apr 15, 2019 |  BC Extra  |  Company News

Management tracks: GW Pharmaceuticals, Aurinia

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) hired Darren Cline as chief commercial officer. He succeeds Julian Gangolli who is retiring. Cline was EVP, commercial at Seattle Genetics Inc. (NASDAQ:SGEN). Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) hired...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
00:03 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Allergan's modified abicipar pegol decreases intraocular inflammation

Ahead of a BLA submission to FDA this half for AMD therapy abicipar pegol, Allergan and Molecular Partners reported top-line safety data from the Phase II MAPLE trial showing that an optimized formulation of the...
06:03 , Apr 11, 2019 |  BioCentury  |  Finance

Syncona eyes a matching pair

Ten months after rounding out its gene therapy strategy with the last two investments in a five-company portfolio, Syncona has decided that two of its companies will fare better as a single entity. Syncona Ltd....
13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Cell and mouse studies identified an ALK-targeting antibody-drug conjugate (ADC) that could help treat neuroblastoma. The ADC consists of an anti-ALK mAb linked to the generic chemotherapy drug thienoindole....
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
18:24 , Apr 5, 2019 |  BioCentury  |  Product Development

Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs

In separate sessions at AACR, FDA’s Oncology chief Richard Pazdur’s pointed comments and questions to PD-1/PD-L1 companies made it clear that he thinks patients are getting hurt from pharmas’ failure to collaborate and the high...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
22:23 , Apr 1, 2019 |  BC Extra  |  Clinical News

Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib...
03:13 , Mar 29, 2019 |  BC Extra  |  Company News

Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal

AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs. Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they...